Previous 10 |
IRVING, Texas, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, February 28 th , 2...
Final results from a Phase 2 clinical trial, PHOENIX , evaluating Reata Pharmaceuticals' ( RETA +1.7% ) bardoxolone methyl in patients with rare types of chronic kidney disease (CKD) showed a treatment effect. The company first reported the positive outcome in September 2018. More ...
STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER 12 WEEKS OF TREATMENT BARDOXOLONE METHYL SIGNIFICANTLY IMPROVED KIDNEY FUNCTION IN PATIENTS FROM ALL FOUR COHORTS OF PHOENIX BARDOXOLONE METHYL SIGNIFI...
NEW YORK,, Feb. 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LPL Financial Holdings Inc. (NASDAQ:LPLA), The Andersons, Inc. (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023